IJR News — today's news from every side
+5 Dana Whitfield I hope the expanded use leads to better access overall, though real-world results and side effect management will matter just as much as the trial numbers.+31 Maya Lindstrom Allen seems more realistic on insurance by balancing flexibility for companies with real accountability.
+5 Tom Gallagher Spreading out the vaccines over time could lower any risks involved, even if the autism link needs more proof.Dr. David Crean Book Guides Biopharma Leaders on Commercialization x/david-crean — Sep 18, 2026 A new book, Dual Fluency: Bridging Science, Capital, and Governance in Life Sciences by Dr. David H. Crean, offers a practical blueprint for biopharma to move from discovery to commercialization by focusing on three core translations—Data to Capital, Discovery to Deal, and Bench to Boardroom—along with Capital Stack Optimization. Aimed at scientist-founders, pre-commercial CEOs, BD executives, and investors, the work promises actionable risk-reduction insights and will be available on Amazon and major bookstores through Cardiff Advisory LLC. +5 Jared Kim This book seems helpful for scientist founders who struggle turning research into actual funding and governance plans.